Kuria Therapeutics and SCOHIA PHARMA Announce Strategic Licensing Agreement for Ophthalmic and Dermal Rights to SCO-116, A Novel Nrf2 Activator

KANAGAWA, Japan & LITTLE ROCK, Ark.--(BUSINESS WIRE)--Kuria Therapeutics, Inc., a US pharmaceutical company developing novel therapeutics for ophthalmic and dermal diseases, and SCOHIA PHARMA, Inc, a Japanese biotech company dedicated to developing medicines for lifestyle-related diseases with high unmet needs, today announced that the companies have entered into a licensing agreement under which Kuria may develop, manufacture, and commercialize worldwide the locally delivered formulations of S